LT5351B - Vakcinos kompozicijos gangliozido pagrindu, skirtos įvedimui po oda - Google Patents

Vakcinos kompozicijos gangliozido pagrindu, skirtos įvedimui po oda Download PDF

Info

Publication number: LT5351B
Authority: LT; Lithuania
Prior art keywords: vssp; group; acgm3; gangliosides; immunological
Prior art date: 2003-02-27

Application number

LT2005087A

Other languages

English (en)

Lithuanian (lt)

Other versions

LT2005087A (en

Inventor

Luis Enrrique Fernandez Molina

Circle Mesa Pardillo

Original Assignee

Centro De Immunologia Molecular

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-02-27

Filing date

2005-09-21

Publication date

2006-07-25

2005-09-21 Application filed by Centro De Immunologia Molecular filed Critical Centro De Immunologia Molecular

2006-04-25 Publication of LT2005087A publication Critical patent/LT2005087A/xx

2006-07-25 Publication of LT5351B publication Critical patent/LT5351B/lt

Links

229960005486 vaccine Drugs 0.000 title claims abstract description 42
239000000203 mixture Substances 0.000 title claims abstract description 38
150000002270 gangliosides Chemical class 0.000 title claims abstract description 25
238000007920 subcutaneous administration Methods 0.000 claims abstract description 10
239000000568 immunological adjuvant Substances 0.000 claims description 11
230000001900 immune effect Effects 0.000 claims description 8
230000028993 immune response Effects 0.000 claims description 6
239000000427 antigen Substances 0.000 claims description 4
102000036639 antigens Human genes 0.000 claims description 4
108091007433 antigens Proteins 0.000 claims description 4
239000006185 dispersion Substances 0.000 claims description 3
230000004936 stimulating effect Effects 0.000 claims 1
239000002671 adjuvant Substances 0.000 abstract description 21
238000011282 treatment Methods 0.000 abstract description 5
241000588650 Neisseria meningitidis Species 0.000 abstract description 4
238000002347 injection Methods 0.000 abstract description 4
239000007924 injection Substances 0.000 abstract description 4
101710116435 Outer membrane protein Proteins 0.000 abstract description 2
108010030416 proteoliposomes Proteins 0.000 abstract description 2
206010028980 Neoplasm Diseases 0.000 description 19
241001465754 Metazoa Species 0.000 description 14
238000009472 formulation Methods 0.000 description 10
230000004083 survival effect Effects 0.000 description 8
241000699670 Mus sp. Species 0.000 description 7
238000002255 vaccination Methods 0.000 description 5
230000000890 antigenic effect Effects 0.000 description 3
230000000694 effects Effects 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
230000002163 immunogen Effects 0.000 description 3
238000007918 intramuscular administration Methods 0.000 description 3
238000001325 log-rank test Methods 0.000 description 3
238000000034 method Methods 0.000 description 3
238000011160 research Methods 0.000 description 3
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
208000023275 Autoimmune disease Diseases 0.000 description 2
239000000872 buffer Substances 0.000 description 2
229940022399 cancer vaccine Drugs 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
244000144993 groups of animals Species 0.000 description 2
238000011081 inoculation Methods 0.000 description 2
201000001441 melanoma Diseases 0.000 description 2
239000008363 phosphate buffer Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
230000004614 tumor growth Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
206010006187 Breast cancer Diseases 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
206010018691 Granuloma Diseases 0.000 description 1
238000000585 Mann–Whitney U test Methods 0.000 description 1
241001529936 Murinae Species 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
-1 VSSP results Chemical class 0.000 description 1
206010000269 abscess Diseases 0.000 description 1
230000002411 adverse Effects 0.000 description 1
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
238000009566 cancer vaccine Methods 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
230000020411 cell activation Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
208000037976 chronic inflammation Diseases 0.000 description 1
230000006020 chronic inflammation Effects 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000004927 fusion Effects 0.000 description 1
GIVLTTJNORAZON-HDBOBKCLSA-N ganglioside GM2 (18:0) Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 GIVLTTJNORAZON-HDBOBKCLSA-N 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
231100000344 non-irritating Toxicity 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
238000009520 phase I clinical trial Methods 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
230000002265 prevention Effects 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
239000002904 solvent Substances 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Oncology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Communicable Diseases (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)

LT2005087A 2003-02-27 2005-09-21 Vakcinos kompozicijos gangliozido pagrindu, skirtos įvedimui po oda LT5351B (lt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CU20030047A CU23257A1 (es)	2003-02-27	2003-02-27	COMPOSICIONES VACUNALES A BASE DE GANGLIOSIDOS PARA LA ADMINISTRACION SUBCUTáNEA

Publications (2)

Publication Number	Publication Date
LT2005087A LT2005087A (en)	2006-04-25
LT5351B true LT5351B (lt)	2006-07-25

Family

ID=40091613

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LT2005087A LT5351B (lt)	2003-02-27	2005-09-21	Vakcinos kompozicijos gangliozido pagrindu, skirtos įvedimui po oda

Country Status (36)

Country	Link
US (1)	US8591917B2 (de)
EP (1)	EP1604683B1 (de)
JP (1)	JP4729475B2 (de)
KR (1)	KR100703570B1 (de)
CN (1)	CN100418576C (de)
AR (1)	AR043377A1 (de)
AT (1)	ATE353668T1 (de)
AU (1)	AU2004216554B2 (de)
BR (1)	BRPI0407854B1 (de)
CA (1)	CA2535214C (de)
CL (1)	CL2004000374A1 (de)
CR (1)	CR7965A (de)
CU (1)	CU23257A1 (de)
CY (1)	CY1106668T1 (de)
DE (1)	DE602004004768T2 (de)
DK (1)	DK1604683T3 (de)
EA (1)	EA008905B1 (de)
EC (1)	ECSP055978A (de)
EG (1)	EG26446A (de)
ES (1)	ES2280948T3 (de)
GE (1)	GEP20074120B (de)
HR (1)	HRP20050763A2 (de)
IL (1)	IL170355A (de)
LT (1)	LT5351B (de)
LV (1)	LV13400B (de)
MY (1)	MY139811A (de)
NZ (1)	NZ541952A (de)
PE (1)	PE20040955A1 (de)
PT (1)	PT1604683E (de)
RS (1)	RS20050664A (de)
SI (1)	SI1604683T1 (de)
TN (1)	TNSN05209A1 (de)
TW (1)	TWI344372B (de)
UA (1)	UA80859C2 (de)
UY (1)	UY28207A1 (de)
WO (1)	WO2004075811A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CU24534B1 (es) *	2017-11-06	2021-07-02	Ct Inmunologia Molecular	Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3
CU20170173A7 (es)	2017-12-27	2019-11-04	Ct Inmunologia Molecular	Nano-partículas que contienen el gangliósido gm3 como inmunomoduladoras

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4965198A (en)	1985-12-24	1990-10-23	Konica Corporation	Monoclonal antibody and method of manufacturing hybridoma producing the same
EP0661061A2 (de)	1993-12-29	1995-07-05	Centro de Inmunologia Molecular	Impfstoff geeignet von ein Immunresponz hervorzurufen gegen N-Glycolysierte-Gangliosiden und ihre Anwendung in Antikrebsmittel
US6149921A (en)	1993-12-29	2000-11-21	Centro De Inmunologia Molecular	Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PE20020572A1 (es) *	2000-12-06	2002-07-31	Centro Inmunologia Molecular	Preparaciones para potenciar la inmunogenicidad de antigenos poco inmunogenicos
CA2399325A1 (en) *	2001-08-21	2003-02-21	National Research Council Of Canada	Carbohydrate-based whole cell cancer vaccines

2003
- 2003-02-27 CU CU20030047A patent/CU23257A1/es unknown
2004
- 2004-02-24 AR ARP040100571A patent/AR043377A1/es not_active Application Discontinuation
- 2004-02-24 PE PE2004000186A patent/PE20040955A1/es not_active Application Discontinuation
- 2004-02-25 TW TW093104808A patent/TWI344372B/zh not_active IP Right Cessation
- 2004-02-26 MY MYPI20040641A patent/MY139811A/en unknown
- 2004-02-26 CL CL200400374A patent/CL2004000374A1/es unknown
- 2004-02-27 EP EP04715239A patent/EP1604683B1/de not_active Expired - Lifetime
- 2004-02-27 DK DK04715239T patent/DK1604683T3/da active
- 2004-02-27 CA CA2535214A patent/CA2535214C/en not_active Expired - Lifetime
- 2004-02-27 WO PCT/CU2004/000003 patent/WO2004075811A2/es not_active Ceased
- 2004-02-27 AU AU2004216554A patent/AU2004216554B2/en not_active Expired
- 2004-02-27 AT AT04715239T patent/ATE353668T1/de active
- 2004-02-27 JP JP2006501455A patent/JP4729475B2/ja not_active Expired - Lifetime
- 2004-02-27 UA UAA200508381A patent/UA80859C2/xx unknown
- 2004-02-27 UY UY28207A patent/UY28207A1/es unknown
- 2004-02-27 ES ES04715239T patent/ES2280948T3/es not_active Expired - Lifetime
- 2004-02-27 PT PT04715239T patent/PT1604683E/pt unknown
- 2004-02-27 DE DE602004004768T patent/DE602004004768T2/de not_active Expired - Lifetime
- 2004-02-27 EA EA200501367A patent/EA008905B1/ru not_active IP Right Cessation
- 2004-02-27 CN CNB2004800052015A patent/CN100418576C/zh not_active Expired - Lifetime
- 2004-02-27 BR BRPI0407854-3A patent/BRPI0407854B1/pt not_active IP Right Cessation
- 2004-02-27 GE GEAP20048952A patent/GEP20074120B/en unknown
- 2004-02-27 NZ NZ541952A patent/NZ541952A/en not_active IP Right Cessation
- 2004-02-27 US US10/547,164 patent/US8591917B2/en not_active Expired - Fee Related
- 2004-02-27 KR KR1020057015531A patent/KR100703570B1/ko not_active Expired - Lifetime
- 2004-02-27 RS YUP-2005/0664A patent/RS20050664A/sr unknown
- 2004-02-27 HR HR20050763A patent/HRP20050763A2/hr not_active Application Discontinuation
- 2004-02-27 SI SI200430262T patent/SI1604683T1/sl unknown
2005
- 2005-08-18 IL IL170355A patent/IL170355A/en not_active IP Right Cessation
- 2005-08-20 EG EGPCTNA2005000479A patent/EG26446A/en active
- 2005-08-24 EC EC2005005978A patent/ECSP055978A/es unknown
- 2005-08-26 CR CR7965A patent/CR7965A/es unknown
- 2005-08-26 TN TNP2005000209A patent/TNSN05209A1/en unknown
- 2005-08-29 LV LVP-05-110A patent/LV13400B/en unknown
- 2005-09-21 LT LT2005087A patent/LT5351B/lt not_active IP Right Cessation
2007
- 2007-04-26 CY CY20071100556T patent/CY1106668T1/el unknown

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4965198A (en)	1985-12-24	1990-10-23	Konica Corporation	Monoclonal antibody and method of manufacturing hybridoma producing the same
EP0661061A2 (de)	1993-12-29	1995-07-05	Centro de Inmunologia Molecular	Impfstoff geeignet von ein Immunresponz hervorzurufen gegen N-Glycolysierte-Gangliosiden und ihre Anwendung in Antikrebsmittel
US6149921A (en)	1993-12-29	2000-11-21	Centro De Inmunologia Molecular	Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CARR, A ET AL.: "A purified GM3 ganglioside conjugated vaccine induces specific, adjuvant-dependent and non-transient antitumour activity against B16 mouse melanoma in vitro and in vivo", MELANOMA RESEARCH, 2001, pages 2019 - 227

Also Published As

Publication number	Publication date
CU23257A1 (es)	2008-01-24
EP1604683B1 (de)	2007-02-14
EP1604683A2 (de)	2005-12-14
LV13400B (en)	2006-05-20
CR7965A (es)	2008-10-29
MY139811A (en)	2009-10-30
ATE353668T1 (de)	2007-03-15
CA2535214A1 (en)	2004-09-10
AU2004216554A1 (en)	2004-09-10
HK1087630A1 (zh)	2006-10-20
GEP20074120B (en)	2007-05-25
AR043377A1 (es)	2005-07-27
RS20050664A (sr)	2007-11-15
WO2004075811A3 (es)	2004-10-14
TWI344372B (en)	2011-07-01
KR20060003857A (ko)	2006-01-11
PE20040955A1 (es)	2005-02-03
JP2006519186A (ja)	2006-08-24
KR100703570B1 (ko)	2007-04-09
DK1604683T3 (da)	2007-06-11
CN1753691A (zh)	2006-03-29
ECSP055978A (es)	2006-01-16
US8591917B2 (en)	2013-11-26
SI1604683T1 (sl)	2007-08-31
CY1106668T1 (el)	2012-05-23
DE602004004768T2 (de)	2007-10-11
NZ541952A (en)	2008-06-30
CN100418576C (zh)	2008-09-17
EA008905B1 (ru)	2007-08-31
EA200501367A1 (ru)	2006-02-24
BRPI0407854A (pt)	2006-02-14
IL170355A (en)	2010-05-31
JP4729475B2 (ja)	2011-07-20
CL2004000374A1 (es)	2005-05-06
PT1604683E (pt)	2007-05-31
US20070148181A1 (en)	2007-06-28
AU2004216554B2 (en)	2010-05-20
HRP20050763A2 (en)	2006-06-30
TNSN05209A1 (en)	2007-06-11
BRPI0407854B1 (pt)	2019-02-26
UY28207A1 (es)	2004-09-30
LT2005087A (en)	2006-04-25
EG26446A (en)	2013-11-07
WO2004075811A2 (es)	2004-09-10
DE602004004768D1 (de)	2007-03-29
CA2535214C (en)	2012-01-10
UA80859C2 (en)	2007-11-12
ES2280948T3 (es)	2007-09-16

Legal Events

Date	Code	Title	Description
2013-10-25	MM9A	Lapsed patents	Effective date: 20130227

Publication	Publication Date	Title
TWI449534B (zh)	2014-08-21	利用陽離子性脂質之對映異構體刺激免疫反應
TW200911274A (en)	2009-03-16	Alpha-galatosyl ceramide analogs and their use as immunotherapies
HU229255B1 (en)	2013-10-28	Vaccines
PT988862E (pt)	2007-01-31	Formulação compreendendo um antigénio, um adjuvante indutor de th-1 e um aminoácido pouco solúvel em água, para utilização em imunização
JPH05504756A (ja)	1993-07-22	免疫刺激性を有する組成物と、そのヒトと獣医学用医薬への応用
KR20230129477A (ko)	2023-09-08	글리코알케올 및 면역자극제를 포함하는 아쥬반트
EP2754436B1 (de)	2018-05-16	Hocheffizienter biologisch abbaubarer Dengue-Impfstoff, Herstellungsverfahren, pharmazeutische Zusammensetzung, die diesen enthält
KR101873506B1 (ko)	2018-07-02	양친매성 폴리 아미노산 고분자 기반 백신 면역보조제 조성물
CN100418576C (zh)	2008-09-17	用于皮下施用的基于神经节苷脂的疫苗组合物
Prager et al.	1978	Enhanced response to chemoimmunotherapy and immunoprophylaxis with the use of tumor-associated antigens with a lipophilic agent
JP2016532712A (ja)	2016-10-20	薬物中毒に対するワクチン組成物
HK1087630B (en)	2009-06-19	Subcutaneously-administered ganglioside-based vaccine compositions
WO2025180443A1 (en)	2025-09-04	Adjuvant composition, pharmaceutical composition comprising the same, and method for preventing or treating disease caused by viral infection, bacterial infection, protozoal infection or cancer
US20240024444A1 (en)	2024-01-25	Combined Preparation
JP4217418B2 (ja)	2009-02-04	キトサン誘導性免疫強化
HK1258829A1 (en)	2019-11-22	Vaccine adjuvant composition based on amphiphilic polyamino acid polymer, containing squalene